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Summary
Since apoptosis is impaired in malignant cells overexpressing prosurvival Bcl-2 proteins, drugs mimicking their natural an-
tagonists, BH3-only proteins, might overcome chemoresistance. Of seven putative BH3mimetics tested, only ABT-737 trig-
geredBax/Bak-mediated apoptosis. Despite its high affinity for Bcl-2, Bcl-xL, andBcl-w,many cell types proved refractory to
ABT-737. We show that this resistance reflects ABT-737’s inability to target another prosurvival relative, Mcl-1. Downregu-
lation of Mcl-1 by several strategies conferred sensitivity to ABT-737. Furthermore, enforced Mcl-1 expression in a mouse
lymphomamodel conferred resistance. In contrast, cells overexpressing Bcl-2 remained highly sensitive to ABT-737. Hence,
ABT-737 should prove efficacious in tumors with lowMcl-1 levels, or when combined with agents that inactivate Mcl-1, even
to treat those tumors that overexpress Bcl-2.Introduction
Impaired apoptosis is a central step in tumor development
(Hanahan and Weinberg, 2000) and renders the tumor cell
more resistant to conventional cytotoxic therapy (Johnstone
et al., 2002). Consequently, an attractive approach for antican-
cer therapeutics is to overcome this inherent resistance to apo-
ptosis by directly activating the normal cell death machinery
(Fesik, 2005).
The key regulators of apoptosis are the interacting proteins of
the Bcl-2 family (Cory et al., 2003). Its prosurvival members, Bcl-
xL, Bcl-w, Mcl-1, and A1 (Bfl-1), as well as Bcl-2 itself, are coun-
tered by a subfamily of distantly related death ligands, the BH3-
only proteins (Huang and Strasser, 2000), which sharewith other
family members only the short BH3 interaction domain. When
BH3-only proteins such as Bim, Bad, or Noxa are activated by
developmental cues or intracellular damage, their amphipathic
a-helical BH3 domain inserts into a hydrophobic groove on their
prosurvival target (Liu et al., 2003; Petros et al., 2000; SattlerCANCER CELL 10, 389–399, NOVEMBER 2006 ª2006 ELSEVIER INC. DOet al., 1997). This key interaction initiates apoptosis, but cell
death ensues only in cells that express Bax and/or Bak (Cheng
et al., 2001; Lindsten et al., 2000; Zong et al., 2001), related mul-
tidomain proapoptotic Bcl-2 family members. When activated,
Bax and Bak oligomerize on the mitochondrial outer membrane
and permeabilize it, inducing the release of apoptogenic pro-
teins, including cytochrome c, that promote activation of the
caspases that mediate cellular demolition.
In many tumors, the capacity of the Bcl-2 family to remove
damaged cells is subverted, either because a prosurvival family
member is overexpressed (Cory et al., 2003), or because muta-
tions in the p53 pathway ablate induction by p53 of the BH3-only
proteins Puma and Noxa, which would otherwise trigger apo-
ptosis (Jeffers et al., 2003; Shibue et al., 2003; Villunger et al.,
2003). Nevertheless, nearly all tumors retain the core apoptotic
machinery. Therefore, there is great interest in the prospect of
developing anticancer agents that directly target Bcl-2-like
prosurvival proteins by mimicking the BH3 domain (Baell and
Huang, 2002; Fesik, 2005; Rutledge et al., 2002). A ‘‘BH3S I G N I F I C A N C E
Targeting the prosurvival Bcl-2-like proteins for cancer therapy is attractive because their overactivity promotes tumor formation and
often limits responses to cytotoxic agents. Hence, drugs mimicking their antagonists, BH3-only proteins, offer promise as anticancer
agents. Unlike other putative BH3 mimetics tested, ABT-737 induced apoptosis by the expected mechanism. Because ABT-737 targets
only certain prosurvival proteins (Bcl-2, Bcl-xL, Bcl-w), its efficacy as a single agent is restricted to tumors where prosurvivalMcl-1 is low.
We show that resistant cells canbe sensitized toABT-737byapproaches that downregulate, destabilize, or inactivateMcl-1. Our studies
provide a rational basis for designing clinical trials of this highly promising agent and a benchmark for systematically evaluating BH3
mimetic compounds.I 10.1016/j.ccr.2006.08.027 389
A R T I C L Emimetic’’ should readily kill tumor cells, even those lacking p53
function.
Although targeting a protein-protein interaction for therapeu-
tics is challenging (Cochran, 2001), several candidate BH3 mi-
metics, both peptidic and nonpeptidic, have now been reported
(Baell and Huang, 2002; Oltersdorf et al., 2005; Rutledge et al.,
2002; Walensky et al., 2004). The search for nonpeptidyl small
molecules that might act as killer BH3 ligands has included
both in silico screens (e.g., Wang et al., 2000) and ‘‘wet’’ screen-
ing of compound libraries (e.g., Degterev et al., 2001). Most of
the putative BH3 mimetics so far described, however, have an
affinity for their presumed protein targets that is far lower than
that of BH3-only proteins (Chen et al., 2005; Petros et al.,
2000), and themechanism of their cytotoxic action is not well es-
tablished (Baell and Huang, 2002; Rutledge et al., 2002).
To establish whether putative BH3 mimetics in fact kill via the
Bcl-2-regulated pathway, we have explored whether their cyto-
toxic action requires the expression of Bax and Bak. Surpris-
ingly, six of the seven putative BH3 mimetics tested killed cells
lacking Bax and Bak. The exception was ABT-737, a recently
described compound from Abbott Laboratories (Oltersdorf
et al., 2005). ABT-737 holds great promise, as it avidly binds
the prosurvival proteins most similar to Bcl-2 and induces Bax/
Bak-dependent killing. Nevertheless, with many cells, ABT-
737 was not cytotoxic on its own. Its behavior mirrored that of
the BH3-only protein Bad, which we showed recently to be a rel-
atively weak killer because it cannot engage the more divergent
Bcl-2 homolog Mcl-1 (Chen et al., 2005; Willis et al., 2005).
Recent studies argue that Mcl-1 has a critical, distinctive role
in the control of apoptosis (Cuconati et al., 2003; Nijhawan
et al., 2003; Opferman et al., 2005). Indeed, we find that Mcl-1
greatly constrains the cytotoxic action of ABT-737. Accordingly,
we show that several strategies for downregulatingMcl-1, some
clinically applicable, render diverse cells highly sensitive to ABT-
737, even in the face of high Bcl-2 expression. These findings
have notable implications for the ways potential drugs like
ABT-737 might be used for treating patients with cancer.
Results
Most putative BH3 mimetics do not kill like
BH3-only proteins
BH3-only proteins require Bax or Bak to kill mouse embryo
fibroblasts (MEFs) (Cheng et al., 2001; Zong et al., 2001). As
expected, infection with retroviruses encoding Bim or truncated
Bid (tBid) rapidly killed wild-type (WT) MEFs, but not MEFs lack-
ing both Bax and Bak (Figure 1A). Furthermore, we have found
that MEFs lacking both Bax and Bak exhibit clonogenic survival
even when a BH3-only protein such as Bim is overexpressed
(Figure 1B).
In contrast, Bax/Bak-deficient cells were as sensitive as WT
ones to killing by several small chemical entities reported to
be BH3mimetics: HA14-1 (Wang et al., 2000), BH3I-1 (Degterev
et al., 2001), Compound 6 (Enyedy et al., 2001), Antimycin A
(Tzung et al., 2001), Chelerythrine (Chan et al., 2003), and Gos-
sypol (Kitada et al., 2003), both in short-term (Figures 1C–1H)
and clonogenic survival assays (Figure 1I). Clearly, as their cyto-
toxic activity does not depend on Bax and/or Bak, none of these
compounds functioned solely as a BH3 mimetic. This may re-
flect their affinities for prosurvival targets, which are much lower
(mM range) than those of the BH3-only proteins (nM range) (Chen390et al., 2005; Petros et al., 2000). Solution competition assays
with an optical biosensor confirmed the weak affinities
(Figure 1J) of some of the compounds (HA14-1, BH3I-1, Antimy-
cin A, Gossypol) for their putative targets, in accord with another
recent study (Zhai et al., 2006).
Figure 1. Many putative BH3 mimetics do not kill like BH3-only proteins
A: The viability of wild-type MEFs (WT) or Bax- and Bak-deficient MEFs (DKO)
24 hr after infection with the indicated retroviruses. Expression of the cDNA
encoding the BH3-only protein BimS or tBid was linked by an IRES to that of
GFP, and the viability of GFP+ cells was determined by PI exclusion.
B: Representative wells showing colony formation by wild-type (WT) or Bax/
Bak-deficient (DKO) MEFs after infection with the control parental retrovirus
or one expressing BimL.
C–H: The viability (percent cells excluding PI) of WT or Bax- and Bak-deficient
(DKO) MEFs treated for 24 hr with graded doses of the indicated putative
BH3 mimetics.
I: Colonies formed by wild-type (WT) or Bax/Bak-deficient (DKO) MEFs in the
presence of no treatment, HA14-1, or Antimycin A.
J: The relative affinities (IC50 in nM) of a Bim BH3 peptide (as previously re-
ported; Chen et al., 2005) and several putative BH3 mimetic compounds
for Bcl-2 and/or Bcl-w. The affinities were measured in solution competition
assays (Chen et al., 2005).
Data in A and C–H represent means 6 SD from three independent experi-
ments.CANCER CELL NOVEMBER 2006
A R T I C L EFigure 2. ABT-737 cooperates with Noxa to induce Bax/Bak-dependent killing
A: The viability of wild-type MEFs (WT), Bax/Bak-deficient MEFs (DKO), and Bak- or Bax-singly deficient MEFs was determined by PI exclusion 48 hr after exposure
to ABT-737 (10 mM) or Etoposide (10 mM).
B: ABT-737 is a Bad BH3 mimetic. Based on the relative affinities (IC50 in nM) of ABT-737 for mammalian prosurvival proteins, determined in solution competition
assays (Figure S1A), ABT-737 and Bad bind to the same subset of Bcl-2 prosurvival proteins. According to our model for initiating the apoptotic program (Chen
et al., 2005; Willis et al., 2005), Bad and Noxa are poor inducers of apoptosis individually because each binds only a subset of the prosurvival proteins, whereas
Bim is a potent killer because it binds all of them. By this rationale, ABT-737 (like Bad) should also cooperate with Noxa to kill cells.
C:Noxa triggers Mcl-1 degradation. Immunoblots of lysates prepared from the MEFs after retroviral infection with wild-type Noxa or the 3E mutant (an inactive
mutant that does not bind Mcl-1) probed for Mcl-1 and HSP70 (loading control).
D: Noxa sensitizes wild-type MEFs to ABT-737 killing. Wild-type MEFs expressing wild-type human Noxa or an inactive mutant (Noxa 3E) (Willis et al., 2005) were
exposed to ABT-737 for 8 hr, and their viability was determined.
E: Bax/Bak-deficient MEFs (DKO) are resistant to ABT-737 even when Mcl-1 is targeted. Long-term clonogenic survival of cells exposed to ABT-737. Equal num-
bers of the indicated MEFs, or their counterparts stably expressing Noxa or the inactive Noxa 3E, were plated in media containing vehicle or ABT-737 (1 mM,
replenished after 3 days), and the colonies formed were scored after 6 days. The number of colonies obtained with ABT-737 treatment is expressed as a pro-
portion of colonies formed with the vehicle alone. y, no colonies.
F: Either Bax or Bak can mediate killing by ABT-737 provided Mcl-1 is targeted. Viability of the indicated MEFs stably expressing Noxa was determined 8 hr after
exposure to ABT-737. Note that Bax/Bak-deficient MEFs (DKO) are resistant.
G: Noxa sensitizes FDC-P1 myeloid cells to ABT-737 killing. The viabilities of FDC-P1 cells, retrovirally infected to express Noxa, mutant Noxa 3E, or Bad, were
compared after a 24 hr treatment with graded doses of ABT-737.
Data in A and D–G represent means 6 SD from a representative of three experiments.ABT-737, a Bad-like BH3 mimetic compound
In contrast to these compounds, in solution competition assays
(Chen et al., 2005) the BH3 mimetic ABT-737 (Oltersdorf et al.,
2005) bound with high affinity to Bcl-2, Bcl-xL, and Bcl-w
(IC50 < 10 nM), but not detectably to the more divergent Mcl-1
or A1 (Figure S1A in the Supplemental Data available with this
article online). Furthermore, direct binding studies using isother-
mal calorimetry confirmed tight stoichiometric (1:1) binding of
ABT-737 to Bcl-xL (Figure S1B), akin to the binding of Bim (Fig-
ure S1C), whereas unlike Bim (Figure S1D) the drug did not bind
Mcl-1 (Figure S1B). Thus, ABT-737 targets the same selected
subset of prosurvival proteins as the BH3-only protein Bad
(Chen et al., 2005).
ABT-737 kills through Bax/Bak, but efficient killing also
requires Mcl-1 neutralization
Notably, Bax/Bak-deficient MEFs were completely resistant to
ABT-737 (Figure 2A). However, even WT MEFs were unexpect-
edly refractory to the drug; after 48 hr of exposure to the maxi-
mal dose tested (10 mM), w80% of them remained viableCANCER CELL NOVEMBER 2006(Figure 2A). We hypothesized that the limited cytotoxic action
of ABT-737 reflects its restricted binding spectrum for the
prosurvival proteins (Figure 2B and Figure S1A).
In this regard, we reported recently that the cytotoxic action of
Bad, which ABT-737 closely resembles, can be potently aug-
mented by coexpression of Noxa, which selectively targets
Mcl-1 and A1 (Chen et al., 2005) and promotes Mcl-1 degrada-
tion (Willis et al., 2005). Hence, we tested whether enforced
Noxa expression would render the WT MEFs sensitive to ABT-
737. As expected (Willis et al., 2005), WT Noxa, but not a non-
binding Noxa mutant 3E triggered marked Mcl-1 degradation
(Figure 2C). Importantly, Noxa sensitized the WT cells to ABT-
737 (Figure 2D), but not other cell death inducers (Figure S2
and data not shown). In striking contrast, the Bax/Bak-deficient
MEFs remained entirely resistant, as assessed by either long-
term clonogenicity (Figure 2E) or short-term viability (Figure 2F).
Killing of Noxa-expressing cells required either Bax or Bak, but
the killing was more efficient in the presence of both (Figure 2F).
Sensitization to ABT-737 by Noxa is not restricted to the
MEFs. Themyelomonocytic cell line FDC-P1 proved to be highly391
A R T I C L Eresistant to treatment with ABT-737 (EC50 > 10 mM), but
introduction of Noxa, ineffectual by itself (Chen et al., 2005;
Willis et al., 2005) (data not shown), increased sensitivity over
2000-fold (EC50w5 nM; Figure 2G). In contrast, as anticipated
from the similar binding profiles of ABT-737 and Bad (Fig-
ure 2B), introduction of Bad did not enhance sensitivity, nor
did the inert Noxa mutant 3E (Figure 2G).
The sensitized cells died by apoptosis, as the loss of plasma
membrane integrity (measured by uptake of propidium iodide)
required caspase activity (Figure 3A), and cell death was as-
sociated with release of cytochrome c from mitochondria (Fig-
ure 3B). ABT-737 also caused Bax/Bak-dependent cytochrome
c release in vitro, but only whenMcl-1 had been neutralized with
Noxa (Figure 3C).
We conclude that ABT-737 is a bona fide BH3 mimetic, since
it induces Bax/Bak-mediated cell killing, but that its selective
binding profile limits its cytotoxicity in some cell types. We
Figure 3. ABT-737 induces cytochrome c release and caspase-dependent
apoptosis when Mcl-1 is neutralized
A: Cell death triggered by ABT-737 is caspase dependent. Noxa-expressing
wild-type MEFs were treated with ABT-737 (1 mM), and their viability was as-
sessed by PI exclusion; coincubation with the broad-spectrum caspase in-
hibitor zVAD.fmk (50 mM) abrogated ABT-737 killing at this time point. Data
represent means 6 SD from three independent experiments.
B: ABT-737 induces cytochrome c release when Mcl-1 is neutralized. Noxa-
expressing wild-type (WT) or Bax/Bak-deficient MEFs (DKO) were exposed
to ABT-737 (10 mM for 4 hr), permeabilized with digitonin to wash out any cy-
tochrome c released to the cytosol, and then fixed. Residual mitochondrial
cytochrome c was detected by immunostaining and flow cytometry
(Waterhouse et al., 2004). ABT-737 triggered loss of cytochrome c from the
mitochondria of WT MEFs, as indicated by the peak of weaker staining
(compare filled with unfilled histogram; upper), but not from the Bax/Bak-
deficient DKO MEFs (lower).
C: ABT-737 and Noxa cooperate in vitro to release cytochrome c. Lysates
prepared from wild-type (left) or Bax/Bak-deficient MEFs (DKO; right) stably
expressing Noxa or Bad were incubated with vehicle (2) or 5 mM ABT-737 (+),
before fractionation into the pellet (P) and supernatant (S) fractions. Equiv-
alent fractions were probed for cytochrome c, Bcl-2 (membrane fraction
marker), and Apaf-1 (cytosolic marker).392attribute the ability of Noxa to sensitize otherwise resistant cells
to its capacity to neutralize prosurvival proteins not targeted by
ABT-737. Even though Noxa targets both Mcl-1 and A1 (Chen
et al., 2005), absence of the latter in many cell types (see below
and Willis et al., 2005) points to Mcl-1 as an important predictor
of responsiveness to ABT-737.
Mcl-1 downregulation sensitizes human carcinoma cells
to ABT-737, which initiates apoptosis by inactivating
prosurvival proteins
Having implicated Mcl-1, we next tested whether refractory hu-
man carcinoma cell lines could be sensitized by downregulating
Mcl-1, by retroviral introduction of either Noxa or a specific hu-
man Mcl-1 short hairpin RNA. Immunoblots showed that Mcl-1
levels were markedly downregulated in both HeLa cervical epi-
thelial cells (Figure 4A, bottom) andMCF-7 breast epithelial cells
(Figure 4C, bottom). Importantly, both ways of reducing theMcl-
1 level potently sensitized these cells to ABT-737 in colony for-
mation assays (top panels of Figures 4A and 4C). In striking con-
trast, when Mcl-1 levels were unperturbed (e.g., by the inert
Noxamutant or the vector control), long-termgrowthwasnot im-
paired byABT-737 (Figures 2E, 4A, and 4C). Importantly, reintro-
duction ofmousemcl-1, which is not targetedby the humanmcl-
1-specific RNAi hairpin used, restored colony formation (Figures
4B and 4D), excluding the contribution of nonspecific targets.
ABT-737 does not activate Bax directly
We next considered whether the drug could kill by directly acti-
vating Bax/Bak, as proposed for certain BH3-only proteins (Ku-
wana et al., 2005; Letai et al., 2002). Direct activation appeared
unlikely because most cell types contain both Bax and Bak and
nevertheless tolerate high concentrations of the drugwith no ap-
parent ill effects (Oltersdorf et al., 2005) (Figures 2 and 4A–4D).
Furthermore, we established that ABT-737 does not bind Bax
(Figure S1E) and, when used on cells, only triggered Bax to un-
dergo the conformational alteration that marks its activation
(Willis et al., 2005) if Mcl-1 had been inactivated with Noxa or
by mcl-1 RNAi (Figure 4E). We therefore conclude that ABT-
737 causes Bax/Bak activation indirectly, by binding tightly and
selectively to Bcl-2, Bcl-xL, and Bcl-w (Figure 2 and Figure S1).
ABT-737 effectively counters overexpression of Bcl-2
When ABT-737 is used alone, the experiments above (Figures
2–4) identify Mcl-1 as a key factor that determines if a cell re-
sponds. A1, the other prosurvival protein that the drug fails to
bind (Figure S1A), is not expressed in most tumor cell lines, in-
cludingMCF-7 and HeLa cells (Su et al., 2002), or in MEFs (Willis
et al., 2005). To directly test if A1 also impairs response to ABT-
737, we have exploited a variant Noxa BH3 that we have found
to be highly selective for Mcl-1 over A1 and other prosurvival
proteins, namelymouseNoxaBH3B (mNoxaB), aswell as amu-
tant of it (E74F) that binds bothMcl-1 and A1 (Figure 5A). Each of
these BH3 sequences, inserted within an inert BimS backbone,
was introduced via retroviruses into MEFs engineered to over-
express A1. When treated with ABT-737, the Mcl-1-selective li-
gand (mNoxaB) was less effective at blocking colony growth
than the E74F mutant that binds both guardians (Figure 5B).
Hence, A1 can also reduce sensitivity to ABT-737.
Since tumors often overexpress Bcl-2 (Tsujimoto et al., 1985)
or Bcl-xL, we also tested the impact of their overexpression.
Even when Mcl-1 was inactivated (by expressing Noxa), Bcl-xLCANCER CELL NOVEMBER 2006
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(Figure 5C), perhaps by raising the level of ABT-737 targets.
Surprisingly, however, Bcl-2 overexpression did not prevent
Figure 4. Neutralizing Mcl-1 sensitizes different cell types to ABT-737
A–D: Colony formation after continuous exposure to ABT-737 (1 mM, replen-
ished every 3 days) of HeLa (A and B) or MCF-7 cells (C and D) infected with
empty vectors, or stably expressing Noxa, mutant Noxa 3E, RNAi targeting
Mcl-1, or RNAi to an irrelevant target (control RNAi). Introduction of mouse
Mcl-1, which is not targeted by the human-specific Mcl-1 RNAi construct, re-
stored the resistance in HeLa (B) or MCF-7 cells (D) to ABT-737. Clonogenic
survival data (after 7 days) represent means 6 SD from three independent
experiments. A and B: The lower panels are immunoblots for Mcl-1 or
HSP70 (loading control). C and D: The lower panels are immunoblots for
human Mcl-1 (top), mouse Mcl-1 (middle: asterisk indicates residual signal
from human Mcl-1 probe), or HSP70 (lower panel).
E: ABT-737 triggers Bax activation when Mcl-1 is neutralized. HeLa cells ex-
pressing mutant Noxa 3E, Noxa, or Mcl-1 RNAi were treated for 4 hr with
ABT-737 (10 mM), and Bax activation was detected by flow cytometric anal-
ysis after staining permeabilized cells with an antibody (clone 3) that specif-
ically recognizes activated Bax (Willis et al., 2005).CANCER CELL NOVEMBER 2006ABT-737-induced death (Figure 5C), even though its level was
sufficient to inhibit Etoposide-induced apoptosis (Figure 5D).
Thus, if Mcl-1 is inactivated, Bcl-2 overexpression does not
Figure 5. Prosurvival proteins differ in their ability to antagonize ABT-737
A:Noxa variants that selectively neutralize Mcl-1 or both Mcl-1 and A1. While
the human Noxa used in Figures 2–4 (above) binds both Mcl-1 and A1 (Chen
et al., 2005) (Figure 2), the mouse Noxa BH3 B region (mNoxaB) only binds
tightly to Mcl-1 (IC50 60 nM; IC50 > 2 mM for all other prosurvival proteins).
The E74F mutant of mNoxaB binds tightly to both Mcl-1 and A1 (IC50Mcl-1
24 nM, IC50A1 12 nM) but has weaker affinity (IC50 > 2 mM) for all other prosur-
vival proteins. The affinities were measured in solution competition assays
(Chen et al., 2005).
B:A1 expression confers partial resistance to ABT-737. Colony formation after
6 days by parental wild-type MEFs or MEFs stably overexpressing FLAG-
tagged A1 in the presence of ABT-737 (1 mM, replenished after 3 days)
and the indicated BH3 domains, placed within an otherwise inert BimS back-
bone lacking its own BH3 (Chen et al., 2005) and expressed from retroviruses.
C and D: Killing by ABT-737 is not inhibited by Bcl-2 and is only partially
inhibited by Bcl-xL. Wild-type MEFs, or MEFs overexpressing FLAG-tagged
Bcl-xL or Bcl-2, were tested for their sensitivity to ABT-737 (1 mM) in the pres-
ence of human Noxa. The Bcl-2 overexpression did not rescue any colony
formation, even though it inhibited apoptosis induced by 24 hr exposure
to Etoposide (D). y, no colonies.
Data inB–D represent means6 SD from a representative of three experiments.393
A R T I C L Ediminish the cytotoxic activity of ABT-737, and Bcl-xL overex-
pression does so onlymoderately. This suggests that combining
ABT-737 with strategies to inactivate Mcl-1 has therapeutic
potential, even in the many tumors where Bcl-2 is markedly
elevated.
Mcl-1 overexpression confers resistance to ABT-737
in vitro and in a mouse lymphoma model
If inactivation of Mcl-1 sensitizes cells to ABT-737 (Figures 2–5),
then overexpression of Mcl-1 might be expected to attenuate
sensitivity to the drug. Unlike most other cell types that we
have tested, factor-dependent myeloid (FDM) cells (Ekert
et al., 2004) proved to be moderately sensitive to ABT-737. As
predicted, ectopic Mcl-1 expression rendered these cells resis-
tant to ABT-737, whereas Bcl-2 overexpression at much higher
levels had no effect (Figure S3).
To assess the impact of Mcl-1 expression on the response to
ABT-737 in vivo, we engineered lymphomas that stably express
Mcl-1 or Bcl-2. Lymphoma cells derived from two Em-myc/bcl-2
bitransgenic mice (Strasser et al., 1990) were infected with ret-
roviruses expressing Bcl-2 or Mcl-1, or a control virus. When
the infected cells were transplanted into syngeneic mice, the re-
cipients became moribund w30 days later if left untreated or
treated with vehicle alone (Figures 6A and 6B and data not
shown). Significantly, ABT-737 therapy prolonged the survival
of recipient mice transplanted with the control or Bcl-2-trans-
duced tumors by up to 30 days (Figures 6C and 6D). Strikingly,
however, the Mcl-1-transduced tumors proved highly refractory
to ABT-737. Indeed, the mice bearing these tumors succumbed
between 20 and 30 days after transplantation, like the vehicle
control group (compare Figure 6C with Figure 6A and Figure 6D
with Figure 6B).
Thus, our data identify Mcl-1 as a critical barrier to respon-
siveness to ABT-737. Its increased expression renders sensitive
Figure 6. Mcl-1 expression blunts the in vivo response of Em-myc/bcl-2
bitransgenic lymphomas to ABT-737
Two independent progenitor B cell lymphomas (#9 [A and C] and #16 [B
and D]) derived from Em-myc/bcl-2 bitransgenic mice (Strasser et al., 1990)
were infected with the control GFP-expressing retrovirus, or ones coexpress-
ing Bcl-2 or Mcl-1 and GFP. The mice were injected with 106 infected tumor
cells before initiating therapy 4 days later with ABT-737 (75 mg/kg given daily
for 2 weeks by intraperitoneal injection) (C and D) or the vehicle alone (A
and B). ABT-737 improved the survival of mice transplanted with both tumors
even when Bcl-2 was overexpressed. However, Mcl-1-overexpressing lym-
phomas were highly resistant to ABT-737, and these mice died rapidly,
akin to their untreated counterparts. Kaplan-Meier survival curves were
derived from an experiment with three mice in each cohort.394cells resistant in vitro and in vivo (Figure S3 and Figure 6),
whereas its inactivation sensitizes resistant cells (Figures 2–5).
Synergy between ABT-737 and genotoxic agents, even in
the face of Bcl-2 overexpression
Asmost tumor cells do not die when treated with ABT-737 alone
(Oltersdorf et al., 2005), we next explored potential strategies to
sensitize them to it by countering Mcl-1. One therapeutic strat-
egy would be to combine ABT-737 with genotoxic agents, as
several lead to Mcl-1 downregulation (Cuconati et al., 2003; Nij-
hawan et al., 2003;Willis et al., 2005), in part by p53-induced up-
regulation of Noxa (Shibue et al., 2003; Villunger et al., 2003).
Therefore, ABT-737 and genotoxic drugs should exhibit syn-
ergy. Indeed, in accord with results in other cell types (Oltersdorf
et al., 2005), ABT-737 sensitized FDC-P1 cells, by at least
100-fold, to apoptosis induced by Cytosine Arabinoside (Ara-C),
Etoposide, or g-irradiation (Figures S4A–S4C).
As chemoresistance mediated by overexpression of Bcl-2 or
Bcl-xL is a major clinical problem (Cory et al., 2003; Kaufmann
and Vaux, 2003), we also assessed whether the synergy per-
sisted in FDC-P1 cells engineered to overexpress these guard-
ians. As expected (Huang et al., 1997a), these cells were now re-
sistant to Ara-C or Etoposide (Figure 7A). Notably, even in the
face of the overexpressed Bcl-2 or Bcl-xL, ABT-737 showed
striking synergy with all three genotoxic agents (Figures 7B and
7C; Figures S4A–S4C). The Bcl-2-expressing cells were sensi-
tized w100-fold and the Bcl-xL-expressing ones at least 5-
fold. As reported with other triggers of DNA damage (Cuconati
et al., 2003;Nijhawanet al., 2003;Willis et al., 2005), all threegen-
otoxic agents reduced Mcl-1 levels in the myeloid cells (Fig-
ure 7D). Similar effects were observed in Em-myc B lymphoma
cells engineered tooverexpressBcl-2 orBcl-xL (data not shown).
In every case, the sensitization was greater in cells overexpress-
ingBcl-2 thanBcl-xL, even thoughBcl-2wasexpressedat higher
levels than Bcl-xL (Figure S4D; see Discussion).
Removing cytokine support sensitizes cells
overexpressing Bcl-2 or Bcl-xL to ABT-737
Since sensitizing cells to ABT-737 with genotoxic agents
(Figure 7) may be less effective in the many tumors where
p53 mutations blunt genotoxic responses, we considered alter-
native strategies to counter Mcl-1. As Mcl-1 expression is usu-
ally maintained by cytokines in hematopoietic cells (Kozopas
et al., 1993), we reasoned that eliminating cytokine support
might well sensitize such cells to ABT-737, even if Bcl-2
were overexpressed. We therefore tested FDC-P1 cells over-
expressing Bcl-2 or Bcl-xL, which tolerate prolonged IL-3
deprivation (Vaux et al., 1988). Upon IL-3 withdrawal, the
Mcl-1 level dropped significantly and that of the BH3-only pro-
tein Bim rose (Figure 8A), but the overexpressed Bcl-2 or Bcl-xL
prevented apoptosis. Nevertheless, the IL-3-deprived Bcl-2-
overexpressing cells were now readily killed by ABT-737, their
sensitivity rising by approximately three orders of magnitude
(Figure 8B). The starved FDC-P1 cells overexpressing Bcl-xL
were also sensitized to ABT-737, albeit to a much lesser degree
(Figure 8B).
These results suggest that combining ABT-737 with selected
cytokine antagonists in order to reduceMcl-1 levels might be an
effective strategy to eliminate Bcl-2-overexpressing malignan-
cies in vivo.CANCER CELL NOVEMBER 2006
A R T I C L EFigure 7. ABT-737 potently sensitizes cells overexpressing Bcl-2 to genotoxic
agents
A: Bcl-2 or Bcl-xL overexpression renders FDC-P1 cells resistant to genotoxic
agents. FDC-P1 cells or FDC-P1 cells overexpressing Bcl-2 or Bcl-xL were
treated with Etoposide (25 mM) or Cytosine Arabinoside (25 mM) for 24 hr,
and viability was determined by PI exclusion.
B and C: FDC-P1 cells overexpressing Bcl-2 (B) or Bcl-xL (C) were treated with
ABT-737 (0–10 mM) and Etoposide (25 mM) or Cytosine Arabinoside (Ara-C; 25
mM) or no other drug (none) for 24 hr, and viability was determined by PI ex-
clusion. Filled lines, fold increase in killing efficacy; hatched lines, EC50
values.
D: Cytotoxic agents trigger Mcl-1 degradation. Equivalent amounts of ly-
sates prepared from cells overexpressing Bcl-2 or Bcl-xL that were left un-
treated or exposed to Etoposide for 24 hr (25 mM) or Ara-C (25 mM) were
probed for Mcl-1 or HSP70 (loading control).
Data in A–C represent means 6 SD from a representative experiment.CANCER CELL NOVEMBER 2006Inhibitors of Mcl-1 production also sensitize cells
to ABT-737
Since bothmcl-1 mRNA and Mcl-1 protein have very short half-
lives (Craig, 2002), strategies that reduce synthesis at either
level may render cells sensitive to ABT-737. Notably, the cy-
clin-dependent kinase inhibitor Seliciclib (R-roscovitine/
CYC202), now in phase II clinical trials, has recently been shown
to act by blocking production ofmcl-1 mRNA (MacCallum et al.,
2005; Raje et al., 2005). Indeed, we found that both Seliciclib
and the protein synthesis inhibitor cycloheximide (CHX) reduced
Mcl-1 levels (Figure 8C) and markedly boosted the action of
ABT-737 in HeLa carcinoma cells (Figure 8D) andmodestly aug-
mented it in MEFs (data not shown). Thus, strategies exploiting
the lability of Mcl-1 have promise.
Discussion
A critical but challenging task with any new therapeutic agent,
such as a BH3 mimetic, is determining its biological mechanism
of action. We reasoned that any agents mimicking the BH3-only
proteins must act through their essential downstream effectors,
Figure 8. Alternative ways to target Mcl-1 and sensitize cells to ABT-737
A: IL-3 withdrawal triggers Mcl-1 degradation and Bim accumulation in FDC-
P1 cells. Lysates prepared from Bcl-2-overexpressing FDC-P1 cells grown for
0–24 hr in the absence of their essential growth factor, IL-3, were blotted for
Mcl-1, Bim, or HSP70 (loading control).
B: IL-3 deprivation sensitizes FDC-P1 cells overexpressing Bcl-2 (squares) or
Bcl-xL (circles) to ABT-737. Viability was determined for the cells, cultured
with (filled symbols) or without (unfilled symbols) IL-3 and exposed to ABT-
737 (0–10 mM) for 24 hr.
C: The protein synthesis inhibitor cycloheximide (CHX) and the CDK inhibitor
Seliciclib both reduce Mcl-1 expression. HeLa cells were treated with 50 mg/
ml cycloheximide or 30 mM Seliciclib (R-roscovitine/CYC202) for 12 hr, and
Mcl-1 expression was measured by immunoblotting (HSP70, loading control).
D:HeLa cells were left untreated or treated with 2.5 mM ABT-737, 50 mg/ml cy-
cloheximide, or 30 mM Seliciclib (R-roscovitine/CYC202), or combinations of
ABT-737 with cycloheximide or Seliciclib, for 14 hr. Statistical analyses were
performed using a two-tailed unpaired Student’s t test.
Data in BandD represent means6 SD from three independent experiments.395
A R T I C L EBax and Bak (Cheng et al., 2001; Lindsten et al., 2000; Zong
et al., 2001). Hence, we compared the ability of putative BH3mi-
metics to kill WT cells and equivalent cells deficient for Bax and
Bak. Six of the seven BH3 mimetic compounds tested at doses
previously reported to be efficacious caused nonspecific toxic-
ity, as they killed cells independently of Bax/Bak (Figure 1). Al-
though these compounds bind Bcl-2-like proteins with low affin-
ities, their predominant cytotoxic activity thus seems to be
mediated through pathway(s) other than those regulated by
Bcl-2. This nonspecific activity presumably would limit their
therapeutic efficacy and potentially provoke undesirable side
effects. Nevertheless, some of them could well be useful leads
for developing higher-affinity derivatives that, like the BH3-only
proteins, kill via Bax or Bak.
Of the compounds tested, only ABT-737, developed by struc-
ture-based design and greatly improved by medicinal chemistry
(Oltersdorf et al., 2005), acted like an authentic BH3 mimetic. Its
highly specific action makes it a good candidate for clinical tri-
als, as its selectivity for its targets should limit undesirable tox-
icity. Consistent with the absence of nonspecific effects in vitro
observed here, ABT-737 appears to cause minimal adverse ef-
fects in mice (Oltersdorf et al., 2005) (A.H.W., K.D.M., A.W.R.,
and D.C.S.H., unpublished data). As ABT-737 effectively targets
Bcl-2, Bcl-xL, and Bcl-w (Figure 2; Oltersdorf et al., 2005), the
compound might have been expected to induce toxic effects
in vivo related to some of the developmental defects in mice
lacking each of those proteins (Cory et al., 2003; Ranger et al.,
2001). However, it seems likely that the transient, and probably
partial, neutralization of these proteins in adult tissues, in con-
trast to their constitutive absence in the developing tissues of
knockout animals, limits collateral damage. Nevertheless,
more detailed in vivo studies will be required to preclude all
adverse side effects.
Howmight ABT-737 be used in the clinic? Our results suggest
that ABT-737 is likely to be most efficacious as a single agent in
those tumorswhereMcl-1 is low, absent, or inactivated. Overex-
pression of A1, which ABT-737 also fails to bind, can also limit its
action, but to a lesser extent (Figure 5B). ABT-737 has shown
single-agent efficacy in many cases of follicular lymphoma,
chronic lymphocytic leukemia, and small-cell lung carcinoma
(Oltersdorf et al., 2005). Significantly, the expression of mcl-1
and a1 mRNA is very low in most malignancies of those types
(see the Gene Expression Omnibus repository at http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=geo).
On the other hand, in those tumors where Mcl-1 is the predom-
inant survival protein, such as multiple myeloma (Zhang et al.,
2002), ABT-737 is unlikely to be effective as a single agent.
Thus, the expression levels of prosurvival proteins, particularly
Mcl-1 andA1, in individual tumors should be valuable prognostic
markers for responses to ABT-737. In small-cell lung cancer cell
lines, resistance to ABT-737 correlates with elevated Mcl-1 ex-
pression (C. Tse, S.K. Tahir, S. Fesik, S. Rosenberg, and S. El-
more, personal communication). Our results also predict that
tumors initially sensitive to ABT-737 may eventually become
resistant by Mcl-1 upregulation. Indeed, the efficacy of ABT-
737 to prolong survival of mice transplanted with a lymphoma
is severely compromised if Mcl-1 is overexpressed (Figure 6).
ABT-737 is likely to be effective (Figures 5–8; Figures S3 and
S4) even in the presence of the very high levels of Bcl-2 or Bcl-xL
found in many tumors (Cory et al., 2003). It has previously been
shown to be highly cytotoxic to most follicular lymphoma cells396(Oltersdorf et al., 2005), in which Bcl-2 is overexpressed due
to translocation of the gene (Cory et al., 2003). We found that
the drug could override overexpression of either Bcl-2 or Bcl-
xL in various scenarios. A striking but consistent finding was
that ABT-737 sensitized cells overexpressing Bcl-2 to a much
greater extent than those overexpressing Bcl-xL (Figures 5, 7,
and 8; Figure S4), even though the affinity of ABT-737 for Bcl-
2 and Bcl-xL is comparable (Figure S1A and Oltersdorf et al.,
2005). This may reflect as yet unexplored differences in the
biological action or regulation of these two proteins.
Although with many cells ABT-737 is not a potent cytotoxic
agent when used alone, we found that most cells could be read-
ily sensitized by eliminating Mcl-1, such as by overexpressing
Noxa, or by downregulating Mcl-1 using RNA interference (Fig-
ures 2–4). We also identified more clinically amenable ways to
reduce Mcl-1 expression. First, Mcl-1 degradation can be in-
duced by DNA damage (Cuconati et al., 2003; Nijhawan et al.,
2003), and we showed that genotoxic agents synergize with
ABT-737, even in cells overexpressing prosurvival Bcl-2 pro-
teins. The potent sensitization observed here (Figure 7;
Figure S4) and by others (Oltersdorf et al., 2005) suggests that
combination therapy with ABT-737 should render genotoxic
agentsmore effective at lower doses, potentially reducing unde-
sirable collateral damage or ensuring more stable remissions
with conventional doses. This approach could be particularly ef-
fective in overcoming the chemoresistance imparted by overex-
pression of Bcl-2 or Bcl-xL (Figure 7). Nevertheless, how well
normal tissues will tolerate ABT-737 in combination with a stan-
dard cytotoxic agent needs further evaluation and may require
optimization of treatment protocols.
Second, the observations that Mcl-1 is a labile protein (Nijha-
wan et al., 2003), maintained in many cell types by cytokine
signaling (Kozopas et al., 1993), prompted us to test whether
cytokine deprivation could sensitize cells to ABT-737. Indeed,
striking synergy was obtained, even when Bcl-2 was overex-
pressed (Figure 8). Hence, antagonists of certain growth factors
may well sensitize tumor cells to ABT-737. For example, antag-
onists of IL-6 or VEGF signalingmay sensitizemultiplemyeloma,
CLL, and perhaps other tumor types (e.g., Huang et al., 2000;
Jourdan et al., 2003; Le Gouill et al., 2004) to ABT-737.
Third, the rapid turnover of mcl-1 mRNA and protein raised
the interesting prospect of targeting intracellular signaling path-
ways that control its transcription and translation. The well toler-
ated cyclin-dependent kinase inhibitor Seliciclib (R-roscovitine/
CYC202), currently in phase II clinical trials for non-small-cell
lung cancer and breast tumors, is now thought to function by im-
pairing RNA synthesis by RNA polymerase II, withmcl-1 mRNA
being a key target because of its rapid turnover (MacCallum
et al., 2005; Raje et al., 2005). Seliciclib showed notable synergy
with ABT-737 in HeLa cells (Figure 8D). We also found that inter-
ference with protein synthesis, using CHX, enhanced ABT-737
action, presumably at least in part by reducingMcl-1 production
(Figure 8D). In accord with this notion, recent results indicate
that the multikinase inhibitor BAY 43-9006, now under phase
II/III clinical evaluation, acts predominantly by inhibiting Mcl-1
translation (Rahmani et al., 2005; Yu et al., 2005). Although
this drug and CHX inhibit translation by different mechanisms
(Rahmani et al., 2005), both these and other agents such as fla-
vopirodol (Kitada et al., 2000) preferentially affect short-lived
proteins like Mcl-1. Thus, the lability of Mcl-1 renders it vulnera-
ble to inhibition in multiple ways.CANCER CELL NOVEMBER 2006
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available therapeutic modality, may well provide substantial
clinical benefit. Indeed, eventually it may prove feasible to en-
hanceMcl-1 degradation by augmenting the activity of the ubiq-
uitin E3 ligase Mule (also known as ARF-BP1, Lasu, HectH9),
which bears a BH3 domain targeting it to Mcl-1 (Zhong et al.,
2005). Furthermore, becausewe have identified a Noxa BH3 do-
main that acts selectively on Mcl-1 (Figure 5A), it should be fea-
sible to develop a BH3mimetic drug that specifically neutralizes
Mcl-1 (and/or A1). Thus, Mcl-1 appears to be an attractive target
for pharmacological intervention, if concerns about the conse-
quences of compromising its essential physiological roles can
be addressed (Opferman et al., 2005; Rinkenberger et al., 2000).
Why is Mcl-1 downregulation so important for killing by ABT-
737 or Bad? First, the rapid degradation of Mcl-1 following cer-
tain cytotoxic stimuli (Cuconati et al., 2003; Nijhawan et al.,
2003; Willis et al., 2005) (Figures 7 and 8) may help to ensure ir-
reversible commitment to apoptosis. Second, since Mcl-1 and
Bcl-xL are the only prosurvival proteins that guard Bak (Willis
et al., 2005), Mcl-1 is the only barrier to Bak-mediated apoptosis
when ABT-737 engages Bcl-xL.
Although the activation of Bax and Bak has been proposed to
require their direct binding by certain ‘‘activator’’ BH3-only pro-
teins, notably Bim and truncated Bid (Kuwana et al., 2005; Letai
et al., 2002), we have proposed that Bak, which is anchored in
the mitochondrial outer membrane, is instead activated simply
by its displacement fromMcl-1 and Bcl-xL by BH3-only proteins
(Willis et al., 2005). In accord with that model, ABT-737 pro-
moted release of cytochrome c from a mitochondrial fraction if
the lysate derived from cells expressing Noxa (to neutralize
Mcl-1), but not cells expressing Bad (Figure 3C). The simplest in-
terpretation of this result is that ABT-737 neutralized the remain-
ing protective prosurvival proteins (e.g., Bcl-xL).
In conclusion, the present studies validate the feasibility of tar-
geting Bcl-2-like proteins using BH3 mimetics such as ABT-737
to induce apoptosis (Oltersdorf et al., 2005). The mechanistic in-
sights provided here suggest ways in which ABT-737 might be
used efficaciously as a single agent and in combination therapy.
They also identify Mcl-1 and A1 as likely prognostic markers for
clinical responses and suggest that Mcl-1 upregulation or stabi-
lization may well emerge as a mechanism of resistance to the
drug. The development of ABT-737 (Oltersdorf et al., 2005), to-
gether with the recent demonstration of selectivity in the action
of BH3-only proteins (Chen et al., 2005) and their prosurvival
targets (Willis et al., 2005), suggest that the Bcl-2-regulated
gateway to apoptosis is ripe for further therapeuticmanipulation.
Experimental procedures
Expression, retroviral, and RNAi constructs
FLAG-tagged mammalian expression vectors (in pEF PGKpuro or pEF
PGKhygro) for Bcl-2 or Bcl-xL, and HA-tagged Bax or Bak, have been de-
scribed (Huang et al., 1997b; O’Connor et al., 1998; Willis et al., 2005), as
have retroviral expression constructs expressing BimS, BimS 4E, or BimL,
and HA-tagged Bad, Noxa, or Noxa 3E (Chen et al., 2005). Constructs for
HA-tagged tBid (amino acids 60–195 of mouse Bid), and FLAG-tagged hu-
man Bcl-2, Bcl-xL, Mcl-1, or A1 (Bfl-1) were made by subcloning into the
same pMIG retroviral vector. The retroviral constructs that target Mcl-1
and/or A1 (Figure 5) replaced residues 51–76 of human BimS with residues
68–93 of mouse Noxa BH3 B (Oda et al., 2000) or a mutation of it (E74F). In
pMIH retroviral constructs, the GFP (green fluorescent protein) cassette of
pMIG is replaced by a hygromycin B resistance gene to link expression of hu-
man Noxa or Noxa 3E, and FLAG-tagged human Bcl-2, Bcl-xL, Mcl-1, or A1,CANCER CELL NOVEMBER 2006to that of the selectable marker. All cDNAs used are of human origin except
for mouse Bad, Bid, and Mcl-1 (in addition to the human gene).
Retroviral vectors for RNA interference were constructed by ligating
annealed oligonucleotides encoding short hairpin sequences into the pRe-
troSuper vector (Brummelkamp et al., 2002). The human Mcl-1 short hairpin
targets the sequence 50-GCAAGAGGATTATGGCTAA. The hairpin oligonu-
cleotides are as follows: Mcl-1 sense, 50-GATCCCCGCAAGAGGATTATGGC
TAATTCAAGAGATTAGCCATAATCCTCTTGCTTTTTGGAAA-30; Mcl-1 anti-
sense, 50-AGCTTTTCCAAAAAGCAAGAGGATTATGGCTAATCTCTTGAATT
AGCCATAATCCTCTTGCGGG-30. The control short hairpin targets the
mouse caspase-12 sequence 50-GGCCACATTGCCAATTCCCA-30. All con-
structs were verified by sequencing, and details of all oligonucleotides and
constructs are available from the authors.
Mouse lymphoma model
Em-myc/bcl-2 bitransgenic mice on a C57BL/6 genetic background develop
disseminated lymphoid tumors with primitive markers at about 6 weeks of
age (Strasser et al., 1990). Tumors from two such mice (#9 and #16) were ex-
panded by injecting 106 cells intravenously into syngeneic WT (nontrans-
genic) recipient males (6–8 weeks old). Once these mice developed tumors,
lymphomatous masses harvested from their mesenteric lymph nodes were
made into a single-cell suspension and infected with the indicated retrovi-
ruses by spin infection (Schmitt et al., 2000). Twenty-four hours later, the in-
fected (GFP+) cells were further expanded in recipient mice and their tumor
mass pooled for use in the lymphoma study.
Cohorts of 6- to 8-week-old mice (n = 3) were inoculated (i.v.) with 106
lymphoma cells infected with the control virus or ones overexpressing
Bcl-2 or Mcl-1. Four days later, a 14 day course of daily i.p. injections of
ABT-737 (75 mg/kg) (Oltersdorf et al., 2005), or vehicle alone, was initiated.
The mice were culled when deemed unwell (lethargy, tremor, hindleg paral-
ysis, >5% weight loss, palpable tumor masses) by the animal husbandry
staff, who were blinded to the experiment.
All mouse experiments were performed in accordance with guidelines ad-
ministered by the Melbourne Health Research Directorate Animal Ethics
Committee.
Other procedures
For details on tissue culture, retroviral infections, cell death induction, and
apoptosis assays; immunoblotting; affinity measurements and solution com-
petition assays; flow cytometric analysis; and in vitro cytochrome c release
assays, see the Supplemental Data.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
four supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/10/5/389/DC1/.
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